Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Busulfan/melphalan/ATG (Bu/Mel/ATG) as a preparative regimen for unrelated donor cord blood transplantation (UCBT): the COBLT experience

Go back to Resources

Busulfan/melphalan/ATG (Bu/Mel/ATG) as a preparative regimen for unrelated donor cord blood transplantation (UCBT): the COBLT experience

Authors:

Location:

Go back to Resources

Audiologic manifestations of patients with post treatment Lyme disease syndrome

Go back to Resources

Audiologic manifestations of patients with post treatment Lyme disease syndrome

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Associations of presbyopia with vision-targeted health-related quality of life

Go back to Resources

Associations of presbyopia with vision-targeted health-related quality of life

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

AREDS Update II: Mortality and Nutritional Risk Factors

Go back to Resources

AREDS Update II: Mortality and Nutritional Risk Factors

Authors:

Location:

Go back to Resources

AREDS Update I: The effect of cataract surgery on progression to advanced AMD

Go back to Resources

AREDS Update I: The effect of cataract surgery on progression to advanced AMD

Authors:

Location:

Go back to Resources

A Study to investigate the Safety and Efficacy of Daclizumab to treat the ocular complications related to the Behcet’s disease

Go back to Resources

A Study to investigate the Safety and Efficacy of Daclizumab to treat the ocular complications related to the Behcet’s disease

Authors:

Location:

Go back to Resources

A severity scale for Age-Related Macular Degeneration (AMD)

Go back to Resources

A severity scale for Age-Related Macular Degeneration (AMD)

Authors:

Location:

Go back to Resources

A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation

Go back to Resources

A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

A National Cancer Institute Pilot Study to Enhance Enrollment in Clinical Trials: The Expanded Participation Project (EPP)

Go back to Resources

A National Cancer Institute Pilot Study to Enhance Enrollment in Clinical Trials: The Expanded Participation Project (EPP)

Authors:

Location:

Go back to Resources

A multicenter randomized double-masked clinical trial of a new formulation of topical Cysteamine for the treatment of Corneal Cystine Crystals in cystinosis

Go back to Resources

A multicenter randomized double-masked clinical trial of a new formulation of topical Cysteamine for the treatment of Corneal Cystine Crystals in cystinosis

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 136
  • Page 137
  • Page 138
  • Page 139
  • Current page 140
  • Page 141
  • Page 142
  • Page 143
  • Page 144
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions